The World Health Organization (WHO) and the International Generic and Biosimilar Medicines Association (IGBA), an umbrella organization with members including the Association for Accessible Medicines, Medicines for Europe, and a number of other national and regional generic and biosimilar organizations, have signed a memorandum of understanding.
The World Health Organization (WHO) and the International Generic and Biosimilar Medicines Association (IGBA), an umbrella organization with members including the Association for Accessible Medicines, Medicines for Europe, and a number of other national and regional generic and biosimilar organizations, have signed a memorandum of understanding.
The agreement highlights the role that the pharmaceutical industry has in helping the WHO maintain tools to facilitate the approval of generics and biosimilars. According to a statement by the WHO, the memorandum will help facilitate cooperation between drug makers and the WHO to reduce the burden of clinical trials for biosimilars, and it will help speed registration and patient access to these drugs.
Among the WHO’s ongoing efforts to increase access to biosimilars is its List of International Comparators, which provides information on reference products that can be used in clinical trials, and its prequalification program, which assesses the quality, safety, and efficacy of medicinal products.
Prequalification ensures that medicines supplied by international procurement agencies meet acceptable standards of quality, safety, and efficacy, and gives the procurement agencies working to distribute drugs in resource-limited countries the choice of a wide range of quality medicines for bulk purchase. Prequalification activities for biosimilars began in 2017.
Earlier this year, speaking at the Medicines for Europe 18th Regulatory and Scientific Affairs Conference, Deus Mubangizi, DrPh, group lead of inspection services on the WHO’s prequalification team, underscored the importance of prequalification activities, and also highlighted ways in which industry and the WHO can partner to facilitate access to medicines.
Mubangizi said there exists a need to reduce the number of repetitive studies conducted for biosimilars, which he said may not always be science-based and may even border on being unethical.
“We approach this issue from the concept that safe, efficacious, good-quality, and affordable medicines should be available for everyone, not just a few,” he said, and explained that eventually using a global reference product in biosimilar development, which could facilitate global approval, is one key way to promote access.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.